Financial Times
Europe’s vaccine hesitancy endangers wider rollout
The pause in the Oxford/AstraZeneca vaccine rollout in Europe this week threatens to undermine immunisation campaigns in developing countries that rely almost exclusively on the jab, say health experts and policymakers.
Calling the decision by a number of European governments to halt its use “irresponsible”, Dr Ayoade Alakija, co-chair of the Africa Vaccine Delivery Alliance, said many poorer countries did not have the luxury of choice but were relying on the relatively cheap and easy-to-store AstraZeneca jab.
“They hit on the one thing that could derail the entire global vaccination campaign for low and middle-income countries,” said Alakija, adding that the resulting vaccine hesitancy in Africa and other developing regions could compound what was already a highly unequal distribution.
“It is not as though we can shop around. The linchpin of our campaign is AstraZeneca. But vaccine confidence is destroyed and conspiracy theories are running amok,” she added.
Cameroon and the Democratic Republic of Congo have suspended the AstraZeneca vaccine rollout after the decision by Germany, Italy, Spain and others to halt use of the jab over concerns of links to blood clots. Indonesia and Thailand also paused its use.
Comment